Back to results
US 6,806,055 B2Granted
HIV envelopolype peptides
AssigneeGenentech, Inc.
InventorsPhillip W. Berman, Gerald R. Nakamura
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeGenentech, Inc.
InventorsPhillip W. Berman, Gerald R. Nakamura
Estimating the term…
A method for the rational design and preparation of vaccines based on HIV envelope polypeptides is described. In one embodiment, the method for making an HIV gp120 subunit vaccine for a geographic region comprises determining neutralizing epitopes in the V2 and/or C4 domains of gp120 of HIV isolates from the geographic region and selecting an HIV strain having gp120 a neutralizing epitope in the V2 or C4 domain which is common among isolates in the geographic region. In a preferred embodiment of the method, neutralizing epitopes for the V2, V3, and C4 domains of gp120 are determined. At least two HIV isolates having different neutralizing epitopes in the V2, V3, or C4 domain are selected and used.to make the vaccine. The invention also provides a multivalent HIV gp120 subunit vaccine. A DNA sequence encoding gp120 from preferred vaccine strains of HIV, GNE8 and GNE16, expression constructs comprising the GNE8-gp120 and GNE16-gp120 encoding DNA under the transcriptional and translational control of a heterologous promoter, and isolated GNE8-gp120 and GNE16-gp120 are also described.
A multivalent HIV subunit gp120 immunogenic composition wherein gp120 present in the immunogenic composition is from at least two isolates and the isolates:
An improved serotyping method for HIV strains comprising determining the serotypes of the V2, V3, and C4 domains of gp120.
A method for making a composition that is capable of eliciting antibodies to HIV, said method comprising:
A multivalent HIV gp120 subunit immunogenic composition wherein gp120 present in the immunogenic composition is from at least two HIV isolates that have different amino acid residues at a position selected from 171, 173 and 429, as numbered from the N-terminal methionine of gp120 from the MN strain of HIV.
An HIV gp120 subunit immunogenic composition comprising an isolated MNGNE-gp120 polypeptide comprising the MNGNE-gp120 amino acid sequence designated SEQ ID NO:1.
An HIV gp120 subunit immunogenic composition comprising a polypeptide comprising a truncated gp120 sequence comprising the V2, V3, and C4 domains of gp120, which sequence is from a gp120 polypeptide selected from the group consisting of MNGNE-gp120, GNE8-gp120, and GNE16-gp120, wherein said polypeptide lacks the gp120 signal sequence.
A composition comprising DNA that expresses gp120, or a fragment thereof, that is capable of eliciting antibodies to HIV, wherein the gp120 is from at least two isolates and the isolates:
A composition comprising DNA that expresses gp120, or a fragment thereof, that is capable of eliciting antibodies to HIV, wherein the gp120 is from at least two HIV isolates that have different amino acid residues at a position selected from 171, 173 and 429, as numbered from the N-terminal methionine of gp120 from the MN strain of HIV.
A composition comprising DNA that expresses a MNGNE-gp120 polypeptide comprising the MNGNE-gp120 amino acid sequence designated SEQ ID NO:1.
A composition comprising DNA that expresses a polypeptide comprising a truncated gp120 sequence comprising the V2, V3, and C4 domains of gp120, which sequence is from a gp120polypeptide selected from the group consisting of MNGNE-gp120, GNE8-gp120, and GNE16-gp120, wherein said polypeptide lacks the gp120 signal sequence.
Dependencies are inferred from the claim text.